Humanized tau antibodies in alzheimer's disease
AssigneeAxon Neuroscience SE
InventorsMichal Novak, Eva Kontsekova, Branislav Kovacech, Rostislav Skrabana
Life of this patent
Estimating the term…
Abstract
The present invention is in the fields of biochemistry, molecular biology, and Alzheimer's disease diagnosis, prevention, and treatment. Provided herein are humanized antibodies against human tau that are capable of discriminating between normal (healthy) and pathological (disease-associated) tau.
Claims21
1-179. (canceled)
A composition comprising a humanized anti-tau antibody, or a tau-binding fragment thereof, and a second therapeutic agent,
- wherein the antibody or binding fragment comprises:
- a heavy chain variable region comprising CDR-H1, CDR-H2, and CDR-H3 of SEQ ID NOs. 1, 2, and 3, respectively, and a framework from human immunoglobulin M65092 (SEQ ID NO. 71);
- a light chain variable region comprising CDR-L1, CDR-L2, and CDR-L3 of SEQ ID NOs. 4, 5, and 6, respectively, and a framework from human immunoglobulin X72449 (SEQ ID NO. 65);
- and
- heavy chain and light chain constant regions each from a human immunoglobulin;
- wherein said heavy chain framework has been substituted at one or more positions selected from 9, 21, 27, 28, 30, 38, 48, 67, 68, 70, and 95;
- said light chain framework has either not been substituted or has been substituted at position 5;
- and wherein said positions are according to Kabat.
A method of treating Alzheimer's Disease or another tauopathy in a subject having, suspected of having, or being prone to have Alzheimer's Disease or another tauopathy, comprising administering to the subject a therapeutically effective amount of a humanized anti-tau antibody, or a tau-binding fragment thereof, and a second therapeutic agent,
- wherein the antibody or binding fragment comprises:
- a heavy chain variable region comprising CDR-H1, CDR-H2, and CDR-H3 of SEQ ID NOs. 1, 2, and 3, respectively, and a framework from human immunoglobulin M65092 (SEQ ID NO. 71);
- a light chain variable region comprising CDR-L1, CDR-L2, and CDR-L3 of SEQ ID NOs. 4, 5, and 6, respectively, and a framework from human immunoglobulin X72449 (SEQ ID NO. 65);
- and
- heavy chain and light chain constant regions each from a human immunoglobulin;
- wherein said heavy chain framework has been substituted at one or more positions selected from 9, 21, 27, 28, 30, 38, 48, 67, 68, 70, and 95;
- said light chain framework has either not been substituted or has been substituted at position 5;
- and wherein said positions are according to Kabat.
Dependencies are inferred from the claim text.